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eEF2K [eEF2 (eukaryotic elongation factor 2) kinase]
phosphorylates and inactivates the translation elongation factor
eEF2. eEF2K is not a member of the main eukaryotic protein
kinase superfamily, but instead belongs to a small group of so-
called α-kinases. The activity of eEF2K is normally dependent
upon Ca2 + and calmodulin. eEF2K has previously been shown
to undergo autophosphorylation, the stoichiometry of which
suggested the existence of multiple sites. In the present study
we have identified several autophosphorylation sites, including
Thr348, Thr353, Ser366 and Ser445, all of which are highly conserved
among vertebrate eEF2Ks. We also identified a number of other
sites, including Ser78, a known site of phosphorylation, and others,
some of which are less well conserved. None of the sites lies in
the catalytic domain, but three affect eEF2K activity. Mutation of
Ser78, Thr348 and Ser366 to a non-phosphorylatable alanine residue
decreased eEF2K activity. Phosphorylation of Thr348 was detected
by immunoblotting after transfecting wild-type eEF2K into HEK
(human embryonic kidney)-293 cells, but not after transfection
with a kinase-inactive construct, confirming that this is indeed a
site of autophosphorylation. Thr348 appears to be constitutively
autophosphorylated in vitro. Interestingly, other recent data
suggest that the corresponding residue in other α-kinases is also
autophosphorylated and contributes to the activation of these
enzymes [Crawley, Gharaei, Ye, Yang, Raveh, London, Schueler-
Furman, Jia and Cote (2011) J. Biol. Chem. 286, 2607–2616].
Ser366 phosphorylation was also detected in intact cells, but was
still observed in the kinase-inactive construct, demonstrating that
this site is phosphorylated not only autocatalytically but also in
trans by other kinases.
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INTRODUCTION
eEF2K [eEF2 (eukaryotic elongation factor 2) kinase] is
a Ca2 + /CaM (calmodulin)-dependent protein kinase, which
phosphorylates eEF2 on Thr56 [1,2], decreasing the affinity
of eEF2 for the ribosome and thereby inhibiting translation
elongation [3,4]. eEF2K contains two main identifiable domains:
the catalytic domain lies in the N-terminal half of the sequence and
belongs to the small group of so-called α-kinases which comprises
six members in mammals [5–8]. Immediately N-terminal to this
lies the CaM-binding region [9,10]. The C-terminal part of eEF2K
contains several features with predicted α-helical structure and has
similarity to the so-called ‘SEL1’ domains that are often involved
in protein–protein interactions [11].
The α-kinases are not homologous with the classical eukaryotic
protein kinase superfamily. However, structural analysis of the
catalytic domain of one α-kinase, the TRP (transient receptor
potential) channel TRPM7 (also termed ChaK, for channel kinase)
revealed similarity to the fold of other protein kinases [12].
Subsequent studies showed that the kinase domain of another
α-kinase, the Dictyostelium discoideum MHCKA (myosin heavy
chain kinase A) adopted a similar structure [13]. However, in
contrast with members of the classical protein kinase family, little
is known about the molecular mechanisms by which the activities
of α-kinases are regulated.
eEF2K is subject to control by phosphorylation by several
kinases which phosphorylate it in trans at sites in the ‘linker’
region between its N-terminal catalytic and C-terminal ‘SEL1’
domains [14–18]. In the presence of Ca2 + and CaM, eEF2K
undergoes autophosphorylation on serine and threonine residues
[19].
Autophosphorylation of other protein kinases modulates their
activity. In particular, two α-kinases, TRPM6 and TRPM7,
undergo extensive autophosphorylation, which enhances their
catalytic activity [20–23]. MHCKA also undergoes substantial
autophosphorylation, which promotes its activation [24,25].
However, most of the autophosphorylated residues in these
proteins lie outside their catalytic domains and, of those that are
located within the kinase domain, several are not conserved in
eEF2K.
So far, there is no information on the identities of the auto-
phosphorylation sites in eEF2K or their functions. In the present
study we have identified the major sites of autophosphorylation
in mammalian eEF2K and demonstrate that at least three of them
modulate its activity. In particular, Thr348, corresponding to an
autophosphorylated threonine residue in MHCKA, is important
for its catalytic activity and Ser366, which has been described as
being a trans phosphorylation site in vivo [15], are important for
the activity of eEF2K in autophosphorylation and against some
substrates.
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EXPERIMENTAL
Materials
The MH-1 peptide RKKFGESEKTKTKEFL [9,24] was
synthesized by V. Stroobant (Ludwig Institute for Cancer
Research, Brussels, Belgium). All routine chemicals and
biochemicals were purchased from BDH-Merck and Sigma–
Aldrich, except for [γ -32P]ATP, which was purchased from
PerkinElmer. Chromatography columns and TLC plates
were purchased from GE Healthcare, and the Ultracell
centrifugation system was from Amicon. The anti-phospho-
Ser78 and -phospho-Thr348 antibodies for eEF2K were generated
by Eurogentec. The anti-phospho-Ser366 antibody was from Cell
Signaling Technology, as was the anti-eEF2K antibody. Anti-
FLAG antibody and alkaline phosphatase immobilized on beaded
agarose were from Sigma–Aldrich. Alkaline phosphatase and
trypsin were from Promega. Solvents and acids for HPLC
and LC (liquid chromatography)–MS were from Biosolve.
Molecular biology
The cDNA encoding human eEF2K was cloned into the vector
pGEX-6P [14] to allow efficient expression as a GST (glutathione
transferase)-fusion protein in Escherichia coli or in PHM vector
for expression of FLAG-tagged eEF2K in HEK-293 cells.
Point mutations were created using the QuikChange® system
(Stratagene).
Protein preparations
Wild-type and mutant human recombinant GST–eEF2K were
expressed in E. coli BL21(DE3) cells by induction with 0.5 mM
isopropyl β-D-thiogalactopyranoside for 16 h at 18 ◦C. After
induction, bacteria were lysed in 50 mM Tris/HCl, pH 7.5,
300 mM NaCl, 1 mM dithiothreitol, 0.1% 2-mercaptoethanol,
0.5% Triton X-100, 0.5 mM PMSF, 0.5 mM benzamidine-
Cl, 5 nM leupeptin, 5 nM aprotinin, 0.02% Brij35 and
0.02% sodium azide. Bacterial lysates were first purified
on DEAE-Sepharose (300–600 mM NaCl gradient) followed
by affinity chromatography on glutathione–Sepharose. Purified
GST–eEF2K preparations in buffer containing 10% (v/v)
glycerol, 50 mM Tris/HCl, pH 7, 150 mM NaCl and 15 mM 2-
mercaptoethanol were concentrated by ultrafiltration (Amicon
Ultracell system, 100 kDa cut-off). SDS/PAGE analysis of full-
length wild-type GST–eEF2K indicated a relative molecular mass
of 130 kDa, and the preparation was approximately 90% pure
(results not shown).
Dephosphorylation of recombinant eEF2K
Recombinant eEF2K (1 mg of protein/ml) was incubated at
room temperature (21 ◦C) with alkaline phosphatase immobilized
on agarose beads (approximately 3000 units/20 μl of reaction
mixture, where 1 unit corresponds to the amount of enzyme that
hydrolyses 1 μmol of p-nitrophenyl phosphate per min at pH 9.8
and 37 ◦C). After 20 min, the mixture was centrifuged at 1000 g
for 3 min to remove the immobilized phosphatase. Dephos-
phorylated eEF2K was then diluted in autophosphorylation buffer.
Autophosphorylation of recombinant eEF2K
Recombinant eEF2K (50 μg/ml) was incubated with Ca2 + /CaM
(0.2 mM/10 μg/ml) and 0.1 mM [γ -32P]MgATP (1000 c.p.m./
pmol) in 40–120 μl of phosphorylation buffer [26] at 30 ◦C.
At various times, aliquots (10 μl) were taken for analysis by
SDS/PAGE in 10% (w/v) mini-gels. Bands corresponding to
eEF2K were cut directly from the gel and dissolved in vials
containing 500 μl of 3% (w/w) H2O2 by heating for 2 h at
80 ◦C prior to liquid scintillation counting. Stoichiometries of 32P
incorporation were calculated as described previously [27].
Phosphorylation site identification by tandem MS, database
searching and analysis
For phosphorylation site identification, wild-type and mutant
GST–eEF2K preparations (5 μg) were incubated in a final
volume of 40 μl with Ca2 + /CaM (0.2 mM/10 μg/ml) and
0.1 mM [γ -32P]MgATP. After 60 min, the reactions were stopped
for trypsin digestion and HPLC [28]. Radioactive peaks were
concentrated and analysed by nanospray ESI (electrospray
ionization)–MS [28]. Alternatively, phosphopeptides were
analysed by LC–tandem MS with the LTQ XL equipped with
a microflow ESI source interfaced to a Dionex Ultimate Plus
Dual gradient pump, a Switchos column switching device and
Famos Autosampler (Dionex). Separation was performed on a
Hypercarb column (180 μm×15 cm; Thermo Fisher Scientific)
equilibrated in solvent A [5% (v/v) acetonitrile and 0.05%
formic acid in water] using a gradient from 0 to 70% solvent B
[80% (v/v) acetonitrile and 0.05% formic acid in water] over
90 min at a flow rate of 1.5 μl/min. The mass spectrometer was
operated in the data-dependent scan routine for the top five ions
with an MS scan range of m/z 300–2000. MSA (Multi Stage
Activation) was enabled for a phosphate neutral loss of 98, 49 or
32.66 with respect to the precursor m/z [29].
Peak lists were generated using the application spectrum
selector in the Proteome Discoverer 1.2 package. From raw
files, tandem MS spectra were exported as individual files in
.dta format with the following settings: peptide mass range, 400–
3500 Da; minimal total ion intensity, 500; and minimal number
of fragment ions, 12. The resulting peak lists were searched
using Sequest against a home-made protein database containing
the human eEF2K sequence (Uniprot O00418) and the GST
tag. The following parameters were used: trypsin was selected
with proteolytic cleavage only after arginine and lysine residues;
the number of internal cleavage sites was set to two; the mass
tolerance for precursor and fragment ions was 1.1 Da and
1.0 Da respectively; and the dynamic modifications considered
were + 15.99 Da for oxidized methionine residues and + 79.96
Da for phosphate addition to serine, threonine or tyrosine
residues. Peptide matches were filtered using charge-state against
cross-correlation scores (xcorr) and phosphorylation sites were
validated manually.
2D (two-dimensional) peptide mapping
2D peptide mapping of tryptic peptides from autophosphorylated
eEF2K preparations radiolabelled in vitro was carried out
as described previously [30], except that detection was by
autoradiography and digestion was performed using trypsin in
the presence of the reducing agent tris(2-carboxyethyl)phosphine
at a final concentration of 5 mM. For MS analysis, spots were cut
from the TLC plates and the cellulose was scraped into tubes for
peptide elution with 80 μl of 70% (v/v) acetonitrile and 0.2%
formic acid by overnight incubation at room temperature. After
centrifugation, the supernatants were concentrated to 10 μl under
vacuum for LC–tandem MS analysis as described above.
eEF2K assay
The activity of eEF2K was measured using the ‘MH-1 peptide’ as
a substrate. This peptide is based on the sequence around the site
in Dictyostelium myosin heavy chain that is phosphorylated by
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some α-kinases [24] and also by eEF2K [9]. Wild-type and mutant
eEF2K preparations (2 μg) were allowed to autophosphorylate in
the presence of 0.1 mM non-radioactive MgATP in a final volume
of 20 μl of phosphorylation buffer [26] at 25 ◦C rather than 30 ◦C
to limit thermal inactivation. After 60 min of incubation, aliquots
(2.5 μl) were taken for the eEF2K assay in a final volume of 50 μl
containing 0.1 mM MH-1 peptide and 0.3 mM [γ -32P]MgATP
(500 c.p.m./pmol) at 30 ◦C. Aliquots (10 μl) were taken at various
times up to 10 min of incubation for measurements of initial
rates of 32P incorporation [28]. A protein kinase activity of
1 unit corresponds to the amount of enzyme that catalyses the
incorporation of 1 nmol/min of 32P under the assay conditions.
The activity of eEF2K against eEF2 was measured essentially as
described previously [16], except that eEF2K was pre-incubated
with non-radioactive MgATP to allow autophosphorylation to
occur, prior to addition of eEF2 and [γ -32P]MgATP. Samples
were then taken for analysis by SDS/PAGE/autoradiography at
the indicated times.
Cell culture and immunoblotting
HEK (human embryonic kidney)-293 cells were cultured and
transfected as described previously [31,32]. Immunoblotting
was performed as described previously [33], except that
detection used a LiCor Odyssey instrument rather than enhanced
chemiluminescence.
Protein estimation and statistical analysis
Protein concentrations were determind as described previously
[34] using BSA as the standard. The results are expressed
as the means +− S.E.M. for the indicated number of individual
experiments. The statistical significance of the results was
assessed by two-way ANOVA followed by a Bonferroni post-
test.
RESULTS
Recombinant eEF2K undergoes extensive autophosphorylation
Redpath and Proud [19] showed previously that native
eEF2K from rabbit reticulocytes undergoes extensive Ca2 + /CaM-
dependent autophosphorylation. Consistent with this, recomb-
inant human eEF2K expressed in E. coli also underwent
autophosphorylation in a strictly Ca2 + /CaM-dependent manner
(Figure 1A). Autophosphorylation was time-dependent, reaching
8.05 +− 0.86 (means +− S.E.M., n = 3) mol of phosphate
incorporated/mol of eEF2K after incubation at 30 ◦C for
60 min. Prior dephosphorylation of the eEF2K preparation with
immobilized alkaline phosphatase resulted in a stoichiometry of
autophosphorylation that was slightly less than was observed
with the untreated enzyme after 60 min of incubation, perhaps
owing to slight protein denaturation during treatment (results
not shown). Also, the tryptic phosphopeptide maps of alkaline-
phosphatase-treated against untreated wild-type eEF2K obtained
after 32P-autophosphorylation were similar in terms of spot
distribution and intensity (see Supplementary Figure S1
at http://www.BiochemJ.org/bj/442/bj4420681add.htm). In the
absence of Ca2 + /CaM, the stoichiometry of eEF2K phosphoryla-
tion was only 0.31 +− 0.03 (means +− S.E.M., n = 3), indicating
that autophosphorylation is strongly Ca2 + /CaM-dependent. This
is similar to our results from previous studies [19].
In a recent parallel study, we expressed fragments of eEF2
containing the N-terminal and kinase domains (eEF2K[1–
402]) and the C-terminal region including the SEL1 domains
Figure 1 Recombinant eEF2K undergoes Ca2+ /CaM-dependent auto-
phosphorylation
(A) GST–eEF2K was incubated with [γ -32P]ATP in the presence or absence of Ca2 + /CaM
as described in the Experimental section. At the indicated times, samples were analysed by
SDS/PAGE for measurements of 32P incorporation. The values are means +− S.E.M. (n = 3).
(B) Autophosphorylation was measured as in (A) with the indicated concentrations of wild-type
(WT) eEF2K and eEF2K[S78A] mutant.
(eEF2K[478–725]) in E. coli [35]. The eEF2K[1–402]
fragment itself underwent autophosphorylation and was able to
phosphorylate the eEF2K[478–725] fragment [35], although, as
expected, the latter did not autophosphorylate itself (results not
shown). Taken together, these data indicate that the 1–402 and
478–725 regions each contain one or more autophosphorylation
site(s). A kinase-inactive mutant, eEF2K[K170M], did not
undergo autophosphorylation, as expected [35]. The rate of auto-
phosphorylation of recombinant eEF2K was independent of the
concentration of eEF2K in the assay (Figure 1B), both for
wild-type eEF2K and for a selected autophosphorylation site
mutant, eEF2K[S78A]. This indicates that autophosphorylation
occurs as a cis intramolecular event, since if different eEF2K
proteins phosphorylated each other in cis, the rate would
show a marked dependence upon concentration. These results
are consistent with our previous observations for the native
protein from rabbit reticulocytes [19], therefore indicating that
cis-autophosphorylation is not merely a consequence of the
expression of eEF2K as a GST-fusion protein in E. coli. It is
noteworthy that TRPM7, another member of the α-kinase family,
was also shown to form dimers (at least for the catalytic domain)
[12,36] and another study [37] indicated that recombinant eEF2K
is monomeric.
Identification of autophosphorylation sites in eEF2K by tandem MS
and 2D peptide mapping
We used two complementary experimental approaches to identify
autophosphorylation sites in eEF2K, together with information
on its specificity [38]. eEF2K shows a very strong preference
for threonine over serine residues when assayed using synthetic
peptide substrates (although Redpath and Proud [19] reported
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Figure 2 HPLC profiles of 32P-autophosphorylated wild-type and mutant eEF2K preparations following trypsin digestion
Tryptic phosphopeptides from autophosphorylated eEF2K were separated by reverse-phase HPLC as described in the Experimental section. The major radiolabelled peaks are indicated by roman
numerals. Phosphorylation sites detected in the peaks are summarized in Table 1 and discussed in the text. HPLC profiles are shown for wild-type (WT) eEF2K (A) and the eEF2K[S78A] (B),
eEF2K[T348A] (C), eEF2K[S366A] (D), eEF2K[S491A] (E) and eEF2K[S445A] (F) mutants.
stronger autophosphorylation on serine than threonine residues).
It also showed a marked preference for peptide substrates with
basic residues at the + 1 and + 3 positions relative to the
phosphorylated residue [38] (although the main site for eEF2K in
eEF2, Thr56, only contains a basic residue at the + 3 position).
In the first experimental approach, we allowed recombinant
eEF2K to undergo autophosphorylation in the presence of
Ca2 + /CaM and [γ -32P]MgATP. The radiolabelled protein was
then precipitated and digested with trypsin; the resulting peptides
were then resolved by reverse-phase HPLC. As shown in
Figure 2(A), nine peaks of radioactivity were reproducibly
observed (denoted ‘I’–‘IX’). Selected fractions from these peaks
were then subjected to tandem MS analysis to identify peptides
and pinpoint phosphorylation sites. The results are summarized
in Table 1. The number of peaks is broadly consistent with the
high stoichiometry of autophosphorylation observed, although
some peaks might arise from tryptic ‘missed cleavages’ due to
the presence of proline residues or to a phosphorylated residue
adjacent to the expected cleavage site. For example, peaks V and
VIII contain the same phosphorylated residue (Ser366; see Table 1
for details).
Secondly, tryptic peptides from autophosphorylated radiola-
belled eEF2K were also separated by 2D mapping [first
dimension, electrophoresis at pH 1.9 (separation by charge/mass
ratio); second dimension, chromatography (separation on the
basis of hydrophobicity)]. As shown in Figure 3(A), 12–13
different labelled peptides were observed, including seven major
species (termed ‘A’–‘G’ in Figure 3A) and several minor ones
(termed ‘h’–‘m’). To identify individual sites, spots from the TLC
plate obtained from tryptically digested 32P-autophosphorylated
wild-type eEF2K were cut out and eluted for tandem MS analysis.
Point mutations were then made in eEF2K, on the basis of
the tandem MS data and the information about the substrate
specificity of eEF2K. The HPLC/MS and TLC peptide mapping
experiments were then repeated using the mutant proteins and the
results were compared with those for the wild-type eEF2K.
For 32P-autophosphorylation studies of wild-type compared with
mutants for analysis by HPLC, the experiments were performed
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Table 1 MS analysis of peptides from HPLC peaks and TLC spots
Labelled fractions from autophosphorylated GST–eEF2K wild-type and mutant HPLC runs (Figure 2A) were analysed by nanospray ESI–tandem MS or LC–tandem MS as described in the Experimental
section. Also, spots from TLC plates obtained after autophosphorylation and trypsin digestion of wild-type eEF2K, comparable with the separation pattern seen in Figure 3(A), were taken and eluted
for LC–tandem MS analysis. Phosphopeptides were identified either by multistage activation or by loss of 98 Da upon collision-induced dissociation. The phosphorylated residue (bold) was further
identified by fragmentation in MS3 mode. Residue numbering refers to the sequence of human eEF2K (Uniprot O00418) without the GST tag.
Peak Phosphopeptide sequence(s) from HPLC peaks Phosphorylation sites identified in HPLC peaks Phosphorylation sites identified in TLC spots*
I K467YESDEDS474LGSSGR480 Ser474 Ser474 in spot E
II Y59YSNLTKS66ER68 and Y59YS61NLTKS66ER68 Ser66 and Ser61 Ser61 in spot B
III E434SENSGDSGYPS445EKRGELDDPEPR457 Ser445 Ser445 in spots G and l
IV L342LQSAKT348ILRGT353EEK356 and Y69SSSGSPANS78FHFK82 and L342LQSAKT348ILR351 Thr348, Thr353 and Ser78 Thr348 in spot A
V T364LS366GSRPPLLR374 Ser366
VI W486NLLNS491SR493 Ser491
VII No identification
VIII T364LS366GSRPPLLRPLSENSGDENMSDVTFDSLPSSPSSATPHSQK406 Ser366
IX No identification
*See Figure 3(B) for the lettering of spots.
using the same stock of radioactive ATP and a correction factor
was applied to the results to take account of the radioactive
decay of 32P and for variations in protein amounts as judged by
overall UV absorbance of peaks, thereby allowing a quantitative
evaluation of any differences (Figure 2). The tryptic peptide
maps obtained with the 32P-autophosphorylated mutant eEF2Ks
compared with the 32P-autophosphorylated wild-type are not
quantitative but do provide a qualitative visualization of the
pattern of sites phosphorylated (Figure 4). Variations might arise
owing to differences in the amounts of material loaded on to
the plates, experiments being performed on different days and
exposure times for autoradiography.
Peak I from the HPLC profile obtained with autophosphorylated
wild-type eEF2K (Figure 2A) corresponded to a peptide in which
Ser474 was the phosphorylated residue identified by MS (Table 1).
The peptide contains a N-terminal lysine residue resulting from
a missed cleavage at an Arg-Lys sequence and a basic residue
only at position + 6, which makes it a poor candidate for being
a bona fide autophosphorylation site on the basis of previous
results [38]. Nevertheless, this site is perfectly conserved among
vertebrate eEF2Ks and is located in the ‘linker’ region. This site
has already been identified in vivo from EGF-stimulated HeLa
cells, but showed no temporal change upon stimulation [39]. Peak
I was lost in the HPLC profile of the eEF2K[S474A] mutant,
whereas no other peaks changed (results not shown). Also, there
was no obvious change in the pattern of peptides on the 2D map
from the eEF2K[S474A] mutant (results not shown), suggesting
that this is a relatively minor site.
Peak II contained two versions of the same peptide, either singly
phosphorylated on Ser66 or doubly phosphorylated on Ser61 and
Ser66. A smaller peptide containing only phosphorylated Ser61
and eluting around fraction 6 was sometimes observed in the
HPLC profile (Figures 2B, 2C and 2D). Ser61 is not conserved in
mammalian eEF2K sequences, and Ser66 is replaced by a threonine
residue in some species. Perhaps more importantly, although the
human sequence contains an arginine residue C-terminal to Ser66,
most mammalian sequences do not. These observations suggest
that neither site is a conserved autophosphorylation site, and we
therefore did not study Ser61 or Ser66 further in the present study.
Peak III contained a very long (23 amino acids) tryptic peptide
with two internal missed cleavages at a consecutive Lys-Arg
sequence, and in which Ser445 was the phosphorylated residue.
All vertebrate eEF2K sequences contain a serine residue at this
position, and in all cases it is followed by an arginine residue
at position + 3 (and a lysine residue at + 2). In view of the
Figure 3 2D peptide maps from autophosphorylated wild-type eEF2K
Wild-type eEF2K was allowed to undergo autophosphorylation in the presence of Ca2 + /
CaM and then subjected to tryptic digestion. Phosphopeptides were resolved by electrophoresis
and chromatography (polarity and directions are indicated). Also shown are the position of
the origin, where the peptide samples were applied, “X”, and the final migration position
of the DNP–lysine marker (cross-hatched circle). (A) Representative map of wild-type eEF2K;
(B) schematic summary of peptides; lettering in capitals for major peptides (shown in dark grey)
and in lower case for minor ones (light grey). The peptide shown by the dotted oval (‘m’) was
only observed on maps from the eEF2K[T348A] mutant.
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Figure 4 2D peptide maps from autophosphorylated wild-type eEF2K and
mutants
Wild-type or mutant eEF2K was allowed to undergo autophosphorylation in the presence
of Ca2 + /CaM and then subjected to tryptic digestion. Phosphopeptides were resolved by
electrophoresis and chromatography (polarity and directions are indicated). The positions where
the sample (larger ‘X’) and the DNP–lysine (smaller “x”) were applied, and the final migration
position of the DNP–lysine marker (open circle) are also shown. The maps are derived from
wild-type eEF2K (A), eEF2K[S445A] (B), eEF2K[T348A] (C), eEF2K[T353A] (D), eEF2K[S491A]
(E), eEF2K[S366A] (F) and eEF2K[S78A] (G). The arrows highlight spots that were lost or that
decreased in intensity compared with the map from wild-type eEF2K. All peptide maps were run
at least twice to verify their reproducibility, and similar levels of radioactivity were applied.
highly conserved nature of this site, we created an eEF2K[S445A]
mutant. The major phosphopeptide species ‘G’ and the minor
peptide ‘l’ were both absent from 2D maps derived from this
mutant, thus demonstrating that Ser445 is indeed a significant
site of autophosphorylation in eEF2K (Figure 4B; compare with
wild-type eEF2K in Figures 3A and 4A). HPLC analysis of the
tryptic peptides from the eEF2K[S445A] mutant revealed that
the labelling of peak III was abrogated, confirming that this peak
does indeed correspond to this site (compare Figure 2A with 2F).
Moreover, Ser445 was identified by MS in spots ‘G’ and ‘l’ after
peptide elution from the TLC plate of 32P-autophosphorylated
wild-type eEF2K (Table 1).
Peak IV was the largest single radioactive peak in the profile and
contained a mixture of three different phosphopeptides bearing
three phosphorylation sites, namely Thr348, Thr353 and Ser78.
Thr348 was seen in a singly phosphorylated peptide and, along
with Thr353, in a doubly phosphorylated peptide due to a missed
cleavage (Table 1). We have previously identified Ser78 as a site of
phosphorylation in eEF2K and made a phosphospecific antibody
for this site [33]. To ascertain whether this residue is indeed a
site of autophosphorylation, we incubated recombinant eEF2K
with non-radioactive MgATP for different times, and analysed
the reaction products by SDS/PAGE and immunoblotting with the
anti-phospho-Ser78 antibody. As shown in Figure 5(B), Ser78 does
become phosphorylated during autophosphorylation, but only at
later times (roughly corresponding to the times when a mobility
shift is observed). Since the results in Figure 5(B) show that
Ser78 undergoes autophosphorylation, we also ran 2D maps from
the eEF2K[S78A] mutant (Figure 4G). Although tryptic cleavage
should generate a readily mobile peptide containing this site
(YSSSGSPANpSFHFK), no obvious difference was seen relative
to the maps from wild-type eEF2K, indicating that this is only a
minor site of autophosphorylation. This was further confirmed in
Figure 5 Use of phosphospecific antibodies to study the autophosphoryla-
tion of eEF2K in vitro and in intact cells
(A) Dot blot to establish whether the anti-phospho-Thr348 antibody is truly phosphospecific.
A total of 1 μl of the indicated dilutions of the phosphorylated and non-phosphorylated
versions of the corresponding peptide (10 mg/ml) were applied to the membrane, which was
developed as for Western blot analysis. (B) Recombinant GST–eEF2K expressed in E. coli
was incubated without or with Ca2 + /CaM, as indicated, and non-radioactive ATP for the times
shown. Samples were then analysed by SDS/PAGE followed by Western blot analysis with
the indicated antibodies specific for phospho (P)-Ser78, phospho-Ser366 or phospho-Thr348,
and anti-eEF2K antibody as a loading control. (C) Results for the phosphorylation of
Thr348 and Ser366 in vivo. HEK-293 cells were transfected with a vector encoding either wild-type
(WT) eEF2K or the kinase-defective eEF2K[K170M] mutant. Cells were treated for the indicated
times with 2-deoxyglucose (DOG; 10 mM; after transfer to medium containing 5 mM glucose),
chlorophenylthio-cAMP (CPT-cAMP; 0.5 mM) or forskolin (Forsk; 10 μM); the latter two were
used in the presence of isobutylmethylxanthine (1 mM). Cell lysates were analysed by SDS/PAGE
and immunoblotting using the indicated antibodies. C, control (untreated) cells. (D) Recombinant
GST–eEF2K was incubated, where noted, with non-radioactive MgATP and, in some cases,
Ca2 + /CaM for the indicated times. Samples were then denatured and analysed by SDS/PAGE
and Western blotting using the indicated antibodies. (E) Recombinant GST–eEF2K was either
analysed directly (‘No inc’) or incubated with alkaline phosphatase ( + AP) for the times shown.
Samples were analysed by SDS/PAGE and Western blotting using the indicated antibodies. (F)
Wild-type eEF2K or two kinase-deficient mutants (K/M, eEF2K[K170M]; D/A, eEF2K[D274A])
were analysed by SDS/PAGE and Western blotting using the indicated antibodies.
the HPLC profile of the tryptically digested autophosphorylated
eEF2K[S78A] mutant (Figure 2B), which revealed that no
peaks were lost, but rather the extent of phosphorylation of all
peaks decreased, probably resulting from a decrease in kinase
activity (see below). Ser78 is also conserved among vertebrate
eEF2K sequences.
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Table 2 Conservation of autophosphorylation sites in eEF2K
+ , conserved; ( + ), local conservation weak, but residue probably conserved; − , local conservation strong, site not conserved; single letter code is used to indicate conservative replacements.
Species Ser61 Ser66 Ser78 Thr348 Thr353 Ser366 Ser445 Ser474 Ser491
Human + + + + + + + + +
Mouse + T + + + + + + −
Rat − T + + + + + + −
Cow + + + + + + + + +
Lizard (Anolis carolinensis) + + + + + + + + −
Zebra finch − T + + + + + + +
Zebrafish − T + + + + + + +
Acorn worm (Saccoglossus kowalevskii) − − − + S − T − −
Strongylocentrotus purpuratus − − − + + − − − −
Aplysia californica − − − + − − − + −
Ascaris suum − − − ( + ) S − − ( + ) −
Caenorhabditis elegans − − − ( + ) − − − ( + ) −
Loa loa − − − S S − − − −
Caenorhabditis briggsae − − − ( + ) − − − ( + ) −
Peak IV also contained peptides phosphorylated on Thr348
and/or Thr353. Thr348 is conserved in almost all known eEF2K
sequences [in Loa loa (filarial nematode) it is replaced by a
serine residue], whereas other mammalian eEF2K sequences, and
some other species, contain a threonine residue at the position
corresponding to Thr353 in human eEF2K (Table 2). We therefore
also created eEF2K[T348A] and eEF2K[T353A] mutants. 2D
phosphopeptide mapping of the eEF2K[T348A] mutant showed
that the intensities of spots ‘A’, ‘B’ and ‘C’ decreased (Figure 4C),
whereas a new spot (‘m’) appeared (indicated in Figure 4C).
After eluting peptides from spots cut from the TLC plate obtained
after 32P-autophosphorylation of wild-type eEF2K, we were able
to identify Thr348 in spot ‘A’ and Ser61 in spot ‘B’ by MS
(Table 1). However, using MS analysis, we were unable to identify
any sites in phosphopeptides eluted from spots ‘C’ and ‘m’.
The HPLC profile from the autophosphorylated trypsin-digested
eEF2K[T348A] mutant (Figure 2C) was very different from the
profile seen with wild-type eEF2K, in that peaks IV, V and VI
were all absent. Taken together, the results indicate that mutation
of Thr348 to an alanine residue also affects the phosphorylation
of other less prominent sites (Ser61, Ser78 and Ser491). This
probably reflects the large decrease in activity observed for
the eEF2K[T348A] mutant (see below). Also, because Thr348
immediately follows a potential tryptic cleavage site (Lys347),
the tryptic cleavage patterns of autophosphorylated wild-type
and T348A mutant could be different. It is well known that the
presence of a phosphorylated residue on the C-terminal side of
a trypsin cleavage site can prevent tryptic cleavage [40]. This
could explain the generation of peptides containing more than
one phosphorylated residue, complicating the interpretation of the
HPLC and 2D mapping data. Taken together, the results indicate
that the Thr348 site is present in spot ‘A’ and possibly also in spots
‘B’ and ‘C’ (Figure 3B). Thus Thr348, a highly conserved residue,
is a major site of autophosphorylation, whose mutation to alanine
dramatically affects autophosphorylation at several other sites.
To study the phosphorylation of Thr348, we generated a
phosphospecific antibody which showed clear specificity for
the phosphorylated against the non-phosphorylated peptide
containing Thr348 (Figure 5A). As shown in Figure 5(B), Thr348
phosphorylation in recombinant eEF2K was already detected
at zero time, and so Thr348 phosphorylation probably occurs
extremely rapidly or during expression in E. coli.
2D mapping analysis of the autophosphorylated
eEF2K[T353A] mutant indicated that some of the peptides
that were absent from the maps for eEF2K[T348A] were
also absent from the maps of this mutant, i.e. peptides ‘B’
and ‘C’ (Figure 4D, compare with Figure 3B). In contrast,
for the autophosphorylated eEF2K[T353A] mutant, peptide
‘m’ did not appear on the map. Therefore the results suggest
that the Thr353 site would be present in peptides migrating in
spots ‘B’, ‘C’ and ‘m’ (Figure 3B). The HPLC profile of the
tryptically digested autophosphorylated eEF2K[T353A] mutant
showed no striking differences compared with the profile seen
for autophosphorylated wild-type eEF2K (results not shown),
consistent with the fact that its mutation to alanine did not affect
eEF2K activity (see below).
In peak V, we detected phospho-Ser366 in a peptide resulting
from tryptic cleavage at Arg-Pro. This might seem surprising
given that trypsin should not cleave next to proline. As such,
this residue would be expected to be located in a very long
tryptic peptide (residues 364–406), which was indeed found in
peak VIII. However, trypsin was recently reported to cleave
Arg-Pro or Lys-Pro bonds more frequently than was previously
thought [41]. The Ser366 site is well conserved and already known
to be phosphorylated in vitro, and probably in vivo, by p70
and p90 ribosomal protein S6 kinases [15]. The availability
of a phosphospecific antibody for this site allowed us to
test whether it is indeed autophosphorylated. Immunoblotting
revealed that Ser366 does become phosphorylated when eEF2K
is incubated with Ca2 + /CaM (Figure 5B). Therefore we studied
the autophosphorylation of the eEF2K[S366A] mutant further
by peptide mapping. This revealed that a number of peptides
were absent from the maps compared with wild-type eEF2K,
specifically spots ‘B’, ‘C’, ‘D’ and ‘F’, and the minor species
‘k’ and ‘l’ (Figure 4F; compare with Figure 3B). The fact that
mutation of this residue affects multiple peptides may again be
a consequence of the dramatic effect of mutation of this residue
to decrease kinase activity. The HPLC profile of the tryptically
digested autophosphorylated eEF2K[S366A] mutant (Figure 2D)
revealed that peaks V and VIII were indeed lost compared with the
profile from autophosphorylated wild-type eEF2K (Figure 2A),
confirming the identification of this site. Also, all other peaks
were notably decreased in the HPLC profile of this mutant owing
to a substantial decrease in the eEF2K activity (see below).
Peak VI contained a peptide in which Ser491 was the sole phos-
phorylation site. This residue is not well conserved in mammals,
being replaced, for example, by a proline residue in rodents.
Mutation of this residue to alanine had no clear effect on the 2D
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Figure 6 Autophosphorylation of wild-type and mutant eEF2K preparations and effects on eEF2K activity
(A) The histogram shows stoichiometries of autophosphorylation of the wild-type (WT) and mutant eEF2K preparations calculated after 60 min of incubation and, in (B), a time-course of phosphorylation
of wild-type against the selected mutants is shown. The results are means +− S.E.M., n = 3. (C) eEF2K wild-type and mutant preparations were allowed to autophosphorylate in the presence of
non-radioactive ATP as described in the Experimental section. After 60 min of incubation, aliquots were taken for eEF2K assay with MH-1 as substrate. Activities calculated from initial rates
of 32P-incorporation are shown in the histogram. Values are means +− S.E.M., n = 3 and *P < 0.001 compared with the wild-type. (D) The wild-type and indicated mutant eEF2K preparations were
incubated with [γ -32P]ATP for autophosphorylation as described in the Experimental section. At the indicated times, samples were taken for SDS/PAGE and autoradiography. The bottom panel shows
a Western blot for eEF2K to confirm that equal amounts of wild-type and mutant enzyme were used.
maps (Figure 4E), but did cause the loss of peak VI in the HPLC
trace and a general decrease in overall labelling (Figure 2E; com-
pare with Figure 6B) compared with the 32P-autophosphorylation
labelling profile of wild-type eEF2K (Figure 2A).
We also generated mutants at several other potential
autophosphorylation sites chosen either because they were
sometimes seen in the tandem MS analysis (Ser345 and
Ser500) or because an arginine residue was present at the
+ 3 position (Ser477 and Ser627). However, the maps obtained
after tryptic digestion of autophosphorylated eEF2K[S345A],
eEF2K[S477A], eEF2K[S500A] and eEF2K[S627A] mutants
were indistinguishable from those obtained with wild-type eEF2K
(results not shown), indicating that they are not significant
sites of autophosphorylation (or do not actually undergo
autophosphorylation at all).
Ser359 is a known site of phosphorylation in eEF2K (for p38
MAPKδ (mitogen-activated protein kinase δ)/SAPK4 (stress-
activated protein kinase 4) and Cdc2 (cell division cycle 2)
[14,16]) and is followed by arginine residues at positions + 2 and
+ 4, suggesting that it might be an autophosphorylation site. We
therefore used the relevant phosphospecific antibody to ascertain
whether it is a site of autophosphorylation, but no signal was
observed when eEF2K was incubated with Ca2 + /CaM, even after
45 min of incubation (results not shown). Ser359 does not therefore
appear to be a significant site of autophosphorylation in eEF2K.
Stoichiometry of in vitro autophosphorylation and effects
on eEF2K activity
The time course of autophosphorylation of each mutant eEF2K
preparation was compared with that of the wild-type. Four
eEF2K mutant preparations displayed a similar stoichiometry of
32P-incorporation compared with the wild-type, measured after
60 min of incubation (Figure 6A): {eEF2K[WT], 8.05 +− 0.86
mol of phosphate incorporated/mol of protein; eEF2K[S345A],
6.3 +− 0.71 mol of phosphate incorporated/mol of protein;
eEF2K[T353A], 5.8 +− 0.67 mol of phosphate incorporated/mol
of protein; eEF2K[S445A], 6.2 +− 0.68 mol of phosphate
incorporated/mol of protein; and eEF2K[S474A], 8.1 +− 0.87
mol of phosphate incorporated/mol of protein (means +− S.E.M.,
n = 3)}. These stoichiometries are in general agreement with
the extent of labelling seen in the HPLC profiles of the
mutants compared with wild-type eEF2K (results not shown).
The decreases in stoichiometry observed for eEF2K[S345A],
eEF2K[T353A] and eEF2K[S445A] (Figure 6A) were not
statistically significant and probably reflect the loss of 32P
incorporation by mutation of the site.
Mutation of Ser78 to alanine significantly decreased the
stoichiometry of 32P-incorporation by approximately 50%
compared with the wild-type: the incorporation of 32P into the
eEF2K[S78A] mutant reached 4.01 +− 0.41 mol of phosphate
incorporated /mol of protein (means +− S.E.M., n = 3) (Figures 6A
and 6B). The HPLC profile of the eEF2K[S78A] mutant was
similar to that of the wild-type, except that the overall extent of
labelling was reduced (Figure 2B), suggesting that this mutation
decreases kinase activity. Since Ser78 is located close to the
CaM-binding domain ([9], Figure 7), the observed decrease
could be due to an effect on CaM-induced activation. Three
other mutations each significantly decreased the stoichiometry
of autophosphorylation by approximately 60% compared with
the wild-type (Figures 6A and 6B): eEF2K[T348A], 2.9 +−
0.34 mol of phosphate incorporated/mol of protein;
eEF2K[S366A], 2.6 +− 0.3 mol of phosphate incorporated/mol
of protein; and eEF2K[S491A], 2.5 +− 0.27 mol of phosphate
incorporated/mol of protein (means +− S.E.M., n = 3).
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Figure 7 Location of autophosphorylation sites within the domain structure
of eEF2K
The layout of the eEF2K polypeptide is depicted schematically (and only roughly to scale).
The major sites of autophosphorylation identified in the present study are indicated (black
arrows), with minor ones shown by grey arrows. The dotted arrow indicates that phosphorylated
Thr348 may dock with the phosphate (P-) pocket in the C-terminal lobe of the catalytic domain
to promote eEF2K activity, similar to Thr825 in MHCKA [25]. See the Discussion for further
information.
To assess the effects of autophosphorylation on eEF2K activity
towards the MH-1 substrate peptide, eEF2K wild-type and mutant
preparations were pre-incubated for 60 min with MgATP at
21 ◦C prior to assaying eEF2K activity. The thermal stability
of the proteins was checked by measuring eEF2K activity
towards MH-1 before and after incubation. The eEF2K wild-
type and selected eEF2K[S78A] mutant preparations lost 10–
30% of eEF2K activity during pre-incubation (results not shown).
The activity of eEF2K[S78A] towards MH-1 was decreased by
approximately 50% compared with the activity of eEF2K wild-
type (Figure 6C). Mutation of Thr348 and Ser366 to alanine had
more drastic effects, reducing eEF2K activity of the preparations
by approximately 90 and 95% compared with the wild-type
protein respectively (Figure 6C). To test whether mutation to
negatively charged residues might mimic autophosphorylation
at this position and perhaps create a more active form of
eEF2K, we created eEF2K[T348D] and eEF2K[T348E] mutants
and studied their activities. These two mutants, along with the
eEF2K[T348A] mutant, phosphorylated purified eEF2 poorly
compared with wild-type eEF2K, indicating that in this case
negatively charged residues do not mimic phosphothreonine at
this position (Figure 6D).
Autophosphorylation of eEF2K studied in intact cells using the
anti-phospho-Thr348 antibody
It was clearly important to study the phosphorylation of
Thr348 in eEF2K in intact cells. To do this, HEK-293
cells were transfected with a vector encoding FLAG-tagged
eEF2K and 24 h later were treated with agents known to
activate eEF2K. Treating cells with 2-deoxyglucose depletes
ATP levels, and activates the AMP-activated protein kinase,
which in turn positively regulates eEF2K [18,42], whereas
chlorophenylthio-cAMP and forskolin both cause the activation of
cAMP-dependent protein kinase, another positive regulator
of eEF2K [43,44]. Western blot analysis of lysates derived from
the transfected cells were probed with phospho-Thr348 and FLAG
antisera. As shown in Figure 5(C), the level of phosphorylation
of Thr348 is essentially the same in all cases for wild-type eEF2K,
indicating that it is phosphorylated under basal conditions.
We also made use of a mutant of eEF2K in which Lys170 is
mutated to methionine: this decreases catalytic activity by >99%
[35]. The level of phosphorylation of Thr348 was greatly decreased
for this mutant, being almost undetectable under most conditions
(Figure 5C). Importantly, this demonstrates that phosphorylation
of eEF2K at Thr348 is autocatalytic. We also tested the state of
phosphorylation of Ser366 using a phosphospecific antibody. As
shown in Figure 5(C), this site is still heavily phosphorylated
in the eEF2K[K170M] mutant, indicating that in vivo it is also
phosphorylated by other kinases, such as p70 and p90 ribosomal
protein S6 kinases [15].
Additional evidence that Ser78 and Thr348 are autophosphorylation
sites
We tested the abilities of selected eEF2K mutants to undergo
phosphorylation at Thr348 in vitro. Mutation of Thr353 to alanine
did not affect the phosphorylation of Thr348 (Figure 5D). In
contrast, the eEF2K[S366A] mutant showed greatly reduced basal
phosphorylation of Thr348 (Figure 5D), although phosphorylation
of this site did increase over time when this variant protein
was incubated with MgATP and Ca2 + /CaM. The reduced
autophosphorylation of this mutant is in line with its decreased
activity shown in Figure 6(C).
To assess whether the signals observed with the phosphospecific
antisera truly reflected phosphorylation of the corresponding
residues, recombinant eEF2K produced by E. coli was treated
with alkaline phosphatase for various times prior to analysis
by Western blot. Alkaline phosphatase treatment decreased the
signal for phospho-Ser78 and phospho-Thr348, but not the signal
for phospho-Ser366 (Figure 5E). These results indicate that Ser78
and Thr348 are already phosphorylated but that the signal for Ser366
may be due to reactivity of the antibody with non-phosphorylated
eEF2K. To study this further, we also analysed two mutants
of eEF2K in which catalytic activity is greatly diminished (by
>99%) by mutation of Lys170 to methionine or Asp274 to alanine
[35]. The signals for phospho-Ser78 and phospho-Thr348, but not
for phospho-Ser366, were markedly decreased for both mutant
proteins (Figure 5F). This confirms that the phosphate at Ser78
and Thr348 is introduced by autophosphorylation, and is consistent
with the phospho-Ser366 antibody detecting the unphosphorylated
residue, although other explanations are possible.
DISCUSSION
Our results of the present study confirm and expand earlier
findings [19] that eEF2K undergoes extensive Ca2 + /CaM-
dependent autophosphorylation. Importantly, we now identify
nine sites of autophosphorylation in human eEF2K, consistent
with the observed stoichiometry of approximately 8 mol of
phosphate/mol of enzyme and show that at least three of them
affect phosphorylation of the MH-1 substrate peptide.
Interestingly, our results reveal for the first time that eEF2K
can use serine as well as threonine as a phosphoacceptor, at least
within the eEF2K polypeptide itself, whereas an earlier study
which employed peptides as substrates found that eEF2K exhib-
ited an overwhelming preference for phosphorylation of threonine
residues in that context [38]. In different species, the physiological
substrate eEF2 always has a threonine residue at the position
corresponding to Thr56 in human eEF2, never a serine residue.
That study also indicated that eEF2K strongly preferred to phos-
phorylate residues with basic amino acids at the + 1 and + 3 po-
sitions. Consistent with this, six of the autophosphorylation sites
that we have identified in the present study have a basic residue in
close proximity to the C-terminal side [arginine residues at + 3
(Thr348, Ser366 and Ser445) or + 2 (Ser491 and Ser66, a less prominent
site), or lysine at + 3 (Thr353)]; Ser61 and Ser78 also have a lysine
residue at + 4. Finally, for Ser474, the basic residue is located at
+ 6. Autophosphorylation does not require a basic residue at + 1
(none of the autophosphorylation sites we have identified has a
basic residue at this position, and neither does Thr56 in eEF2 itself).
Several of the major phosphorylation sites are conserved among
vertebrate eEF2K sequences (Table 2), but only one, Thr348, a
critical site for eEF2K activity, is generally conserved in other
phyla as well (e.g. arthropods, echinoderms, molluscs, cnidaria
and nematodes; it is replaced by another phosphoacceptor, serine,
in some nematodes).
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Mutation of Ser78, Thr348, Ser366 or Ser491 to an alanine residue
reduced the stoichiometry of autophosphorylation (Figures 6A
and 6B), but activity measured towards the MH-1 peptide was
most drastically reduced by mutation of Thr348 or Ser366. However,
this may be the consequence of different mechanisms as the HPLC
profiles and activity measurements differ considerably for these
three mutants. One must also bear in mind that mutations may
alter the folding of eEF2K and exert effects unrelated to the role of
given residues as autophosphorylation sites. The T348A mutation
had a very marked impact on autophosphorylation and activity
against both the MH-1 peptide and eEF2. Thus Thr348 may be
considered as a master site whose phosphorylation is important for
phosphorylation at the other sites. It should be noted that Thr348 is
the autophosphorylation site that is closest to the catalytic domain
and is also the most widely conserved one among known eEF2K
sequences from species as divergent as nematodes and sea slugs
(see further discussion of this site below).
Mutation of eEF2K Ser366 to alanine decreased the extent
of overall 32P-incorporation (Figures 2A and 2D). This mutant
also showed a substantial decrease in activity towards the MH-1
peptide similar to that observed for the eEF2K[T348A] mutant.
Thus Ser366 is important for kinase activity against the MH-1
peptide, although it does not apparently affect activity against
eEF2 itself [15].
Although the eEF2K[T348A] (and eEF2K[S366A]) mutant
proteins showed drastically reduced activities towards MH-
1 (Figure 6C), they still underwent autophosphorylation
(Figure 6A), showing an important difference between autokinase
activity and the ability to phosphorylate substrates in trans.
The results for the activity of the S366A mutant against the
MH-1 peptide are surprising given that earlier work found that
this mutant did not show a marked change in activity against
eEF2 itself [15]; this may reflect differences in the requirements
for phosphorylation of the MH-1 peptide and eEF2, which
are clearly distinct [35]. The eEF2K[S491A] variant showed
a similar behaviour to that of eEF2K[S366A] as regards its
impact on the level of autophosphorylation and the HPLC profile,
but it is clearly different in terms of catalytic activity towards
MH-1, which was only slightly altered. This again indicates
that the autophosphorylation and transphosphorylation processes
against different substrates, although sharing common regulatory
mechanisms, also have specific requirements.
We have shown in a recent study that, although fragments
lacking the C-terminal part of eEF2K cannot phosphorylate
eEF2 or the MH-1 peptide, addition of the eEF2K[478–725]
fragment restores their ability to do so, and we suggest that
the C-terminal SEL1-containing region helps to recruit substrates
for phosphorylation by the kinase domain [35]. The sequence
connecting the two domains contains a number of phosphorylation
sites for kinases that regulate the activity of eEF2K (e.g. Ser359
[16], Ser366 [15], Ser396 [17] and Ser398 [18]). It is possible
that phosphorylation of these sites affects eEF2K activity by
altering the conformation of the ‘linker’ region and thereby
the efficiency of the ‘coupling’ between the C-terminal and
kinase domains of eEF2K. In this context, it is notable that
mutation of Ser366 markedly alters activity against the MH-1
peptide.
Interestingly, other α-kinases also undergo autophos-
phorylation. TRPM6 and TRPM7 contain many sites of
autophosphorylation [20] and MHCKA also undergoes auto-
phosphorylation [24,25]. Where known, many of these
autophosphorylation sites lie in regions that are not homologous
with eEF2K; of those that do lie in their homologous kinase
domains, only one corresponds to a potential phosphorylation
site in eEF2K (Ser135), and we did not find this as an
autophosphorylation site, even though it should yield a readily
detectable tryptic phosphopeptide. Crawley et al. [45] identified
several sites of autophosphorylation in MHCKA. Our finding in
the present study that Thr348 is a major site of autophosphorylation
in eEF2K is precisely in accord with their data and predictions
[45]. These authors showed that Thr825 is constitutively
autophosphorylated in MHCKA. This residue, the equivalent of
Thr348 in eEF2K, lies just C-terminal to the catalytic domain. On
the basis of the crystal structure of its catalytic domain together
with biochemical data, they proposed that phosphorylated Thr825
docks with a phosphate-binding pocket in the C-terminal lobe, and
that this interaction stimulates the catalytic activity of MHCKA.
They suggest that a similar mechanism may operate in other
α-kinases [45]. The results of the present study are entirely
consistent with this; Thr348, which we have identified as a major
site of autophosphorylation, lies close to, and on the C-terminal
side of, the catalytic domain, and, in common with Thr825 in
MHCKA, is followed by a hydrophobic residue (isoleucine
in many vertebrate eEF2Ks; replaced by other branched-chain
residues in some other species). Both the phosphate-binding
pocket and the proposed ‘partner’ for the adjacent hydrophobic
residue are conserved among MHCKs and eEF2Ks. It thus
appears likely that autophosphorylation promotes the activity
of these enzymes in similar ways, through the interaction of a
constitutively phosphorylated threonine residue with a conserved
phosphate-binding region. Our observation that replacement of
Thr348 with either a glutamate or aspartate residue generated
a catalytically inactive enzyme is in accordance with the data
of Crawley et al. [45], who found that adding phosphate or
phosphothreonine, but not glutamate or aspartate, could activate
a truncated version of MHCKA that lacks the region containing
Thr825. It is interesting that Thr348 is basally phosphorylated in
human cells; this probably ensures that eEF2K is already ‘primed’
and poised to phosphorylate eEF2.
A surprising finding from our studies is that eEF2K undergoes
autophosphorylation on two sites, which inhibit its activity, Ser78
and Ser366; both sites are phosphorylated in vivo in response to,
e.g., insulin in an mTORC1 (mammalian target of rapamycin
complex 1)-dependent manner [15,33]. An analogous situation is
found for the catalytic α-/β-subunits of AMP-activated protein
kinase, which autophosphorylate on Ser485/Ser491 [28]. However,
protein kinase B also phosphorylates this site, thereby decreasing
the activation of AMP-activated protein kinase by LKB1 [46].
Phosphorylation of Ser78 impairs the interaction of eEF2K with
CaM [33], whereas phosphorylation of Ser366 impairs its activation
by Ca2 + ions [15]. Both of these sites are also autophosphorylated,
and, in the case of Ser78, apparently only at a low level in vitro or
in vivo (results not shown). In contrast, the 2D peptide maps
show that Ser366 is a major site of autophosphorylation. It is
possible that its slow phosphorylation serves to turn off eEF2K
after its activation in response to cellular stresses, by desensitizing
eEF2K to activation by Ca2 + /CaM, thereby allowing translation
elongation to resume.
In conclusion, the results from the present study reveal that
Thr348, and presumably its autophosphorylation, are critical for
the ability of eEF2K to phosphorylate substrates in trans, having
similar effects on the phosphorylation of the MH-1 substrate
peptide. These results suggest that autophosphorylation of eEF2K
may be a prerequisite for the activity of eEF2K, in line with other
α-kinases that have been studied.
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Figure S1 2D autophosphorylation peptide maps of alkaline-phosphatase-
treated compared with untreated wild-type eEF2K
(A) Wild-type eEF2K was first dephosphorylated with alkaline phosphatase and subsequently
allowed to undergo autophosphorylation in the presence of Ca2 + /CaM as described in the
Experimental section of the main text. (B) Wild-type eEF2K phosphorylated in the presence of
Ca2 + /CaM without pre-treatment. After tryptic digestion, phosphopeptides were resolved by 2D
electrophoresis and chromatography (polarity and directions are indicated). The positions where
the sample (larger ‘X’) and the DNP-lysine (smaller ‘x’) were applied, and the final migration
position of the DNP–lysine marker (broken open circle) are also shown.
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